Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients.
Acute phase response
Antiretroviral therapy (ART)
Denosumab
HIV
Osteoporosis
Zoledronate
Journal
Bone reports
ISSN: 2352-1872
Titre abrégé: Bone Rep
Pays: United States
ID NLM: 101646176
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
19
07
2021
revised:
05
09
2021
accepted:
06
09
2021
entrez:
20
9
2021
pubmed:
21
9
2021
medline:
21
9
2021
Statut:
epublish
Résumé
We aimed to compare annual changes in the bone mineral density (BMD) at the lumbar spine (LS) and the femoral neck (FN) in males with HIV-associated osteoporosis treated with either zoledronate (ZOL) or denosumab (Dmab). In this open label, 12-month, prospective, multicenter, cohort study, 23 male people living with HIV (PLWH) under LS-BMD increased within both treatment groups at 12 months (ZOL 5.43% ± 3.60%, In male PLWH under ART requiring osteoporosis treatment both ZOL and Dmab are efficient and well tolerated therapeutic options achieving BMD increases at least for the first year of treatment.
Identifiants
pubmed: 34541262
doi: 10.1016/j.bonr.2021.101128
pii: S2352-1872(21)00385-5
pmc: PMC8441091
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101128Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
P. Makras reports honoraria for lectures and research grants from Amgen and Gilead; A.D. Anastasilakis reports lecture fees from Amgen; P. Petrikkos, A. Kolynou, A. Katsarou, O. Tsachouridou, S. Metallidis, and M.P. Yavropoulou have nothing to declare.
Références
Curr Treat Options Infect Dis. 2017 Mar;9(1):52-67
pubmed: 28413362
Arch Osteoporos. 2019 Mar 15;14(1):39
pubmed: 30877479
Reumatismo. 2021 Apr 19;73(1):54-58
pubmed: 33874648
AIDS. 2012 Apr 24;26(7):825-31
pubmed: 22301411
Curr Opin HIV AIDS. 2014 Jan;9(1):17-26
pubmed: 24263798
Clin Infect Dis. 2011 Apr 15;52(8):1061-8
pubmed: 21398272
J Acquir Immune Defic Syndr. 2020 Jan 1;83(1):1-8
pubmed: 31809356
Viruses. 2020 Dec 17;12(12):
pubmed: 33348583
Calcif Tissue Int. 2011 May;88(5):402-8
pubmed: 21305270
Clin Infect Dis. 2010 Oct 15;51(8):963-72
pubmed: 20828304
J Clin Endocrinol Metab. 2012 Sep;97(9):3161-9
pubmed: 22723310
Eur J Endocrinol. 2018 Jul;179(1):R31-R45
pubmed: 29691303
Lancet HIV. 2017 Aug;4(8):e349-e356
pubmed: 28501495
Clin Infect Dis. 2013 May;56(10):1498-504
pubmed: 23378285
Bone. 2020 Sep;138:115512
pubmed: 32603908
J Clin Endocrinol Metab. 2021 May 12;:
pubmed: 33978745
J Musculoskelet Neuronal Interact. 2017 Dec 1;17(4):292-298
pubmed: 29199188
J Clin Endocrinol Metab. 2007 Apr;92(4):1283-8
pubmed: 17227801
AIDS Rev. 2014 Oct-Dec;16(4):213-22
pubmed: 25300622
J Clin Endocrinol Metab. 2008 Sep;93(9):3499-504
pubmed: 18593764
Expert Opin Drug Saf. 2021 May;20(5):499-501
pubmed: 33372551
Best Pract Res Clin Rheumatol. 2015 Apr;29(2):319-42
pubmed: 26362747
J Clin Endocrinol Metab. 2020 Oct 26;:
pubmed: 33103722
AIDS. 2006 Nov 14;20(17):2165-74
pubmed: 17086056
AIDS. 2000 Mar 10;14(4):F63-7
pubmed: 10770534
N Engl J Med. 2012 Nov;367(18):1714-23
pubmed: 23113482
N Engl J Med. 2007 Nov 1;357(18):1799-809
pubmed: 17878149
Clin Infect Dis. 2010 Oct 15;51(8):937-46
pubmed: 20839968